Published in JAMA on April 06, 2011
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health (2013) 2.85
Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst (2013) 2.45
Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst (2013) 2.21
The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy. J Am Geriatr Soc (2013) 2.11
Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation (2011) 1.88
Premature menopause or early menopause and risk of ischemic stroke. Menopause (2012) 1.84
Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst (2013) 1.60
Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int (2015) 1.53
Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila) (2012) 1.44
Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause (2013) 1.42
Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. J Natl Cancer Inst (2015) 1.41
Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence. Cancer Epidemiol Biomarkers Prev (2012) 1.39
Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst (2012) 1.39
Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab (2011) 1.12
Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci (2011) 1.10
Stroke risk in women: the role of menopause and hormone therapy. Lancet Neurol (2012) 1.10
Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis. Cancer Prev Res (Phila) (2011) 1.09
Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause (2013) 1.08
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res (2012) 1.08
Hormone therapy use in women veterans accessing veterans health administration care: a national cross-sectional study. J Gen Intern Med (2014) 1.07
Estrogen neuroprotection and the critical period hypothesis. Front Neuroendocrinol (2011) 1.03
Hot flashes: a review of pathophysiology and treatment modalities. Oncologist (2011) 1.02
Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovasc Res (2012) 1.01
The potential association between postmenopausal hormone use and primary open-angle glaucoma. JAMA Ophthalmol (2014) 0.99
Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause (2015) 0.98
The treatment of climacteric symptoms. Dtsch Arztebl Int (2012) 0.98
Perimenopause and cognition. Obstet Gynecol Clin North Am (2011) 0.94
From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol (2011) 0.94
Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut (2011) 0.94
Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93
Moving a randomized clinical trial into an observational cohort. Clin Trials (2012) 0.93
Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. Horm Mol Biol Clin Investig (2012) 0.92
Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer (2011) 0.92
Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther (2013) 0.91
The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric (2012) 0.91
The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer (2014) 0.90
Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk. J Mammary Gland Biol Neoplasia (2013) 0.90
Low-dose bisphenol A and estrogen increase ventricular arrhythmias following ischemia-reperfusion in female rat hearts. Food Chem Toxicol (2013) 0.89
Premature menopause and risk of neurological disease: basic mechanisms and clinical implications. Mol Cell Endocrinol (2014) 0.89
Effects of chronic and acute oestrogen replacement therapy in aged animals after experimental stroke. J Neuroendocrinol (2012) 0.88
Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst (2011) 0.88
Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause (2012) 0.87
Factors associated with breast cancer in Puerto Rican women. J Epidemiol Glob Health (2013) 0.87
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res (2013) 0.87
Short-term use of unopposed estrogen: a balance of inferred risks and benefits. JAMA (2011) 0.87
Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Res Treat (2011) 0.87
PPARγ activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol (2013) 0.87
Demographic and health factors associated with enrollment in posttrial studies: the Women's Health Initiative Hormone Therapy Trials. Clin Trials (2013) 0.86
Sex hormone receptor repertoire in breast cancer. Int J Breast Cancer (2013) 0.86
Circulatory estrogen level protects against breast cancer in obese women. Recent Pat Anticancer Drug Discov (2013) 0.86
Estrogen effects on vascular inflammation are age dependent: role of estrogen receptors. Arterioscler Thromb Vasc Biol (2014) 0.85
Empirical evaluation of gene and environment interactions: methods and potential. J Natl Cancer Inst (2011) 0.85
Women's health initiative view of estrogen avoidance and all-cause mortality. Am J Public Health (2013) 0.84
Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative. Curr Opin Lipidol (2013) 0.84
Oestrogen signalling and neuroprotection in cerebral ischaemia. J Neuroendocrinol (2012) 0.83
Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. Brain (2013) 0.83
Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev (2012) 0.83
Positive association of the hepatic lipase gene polymorphism c.514C > T with estrogen replacement therapy response. Lipids Health Dis (2011) 0.83
Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric (2012) 0.82
Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst (2014) 0.82
Effects of hormone therapy on brain structure: A randomized controlled trial. Neurology (2016) 0.82
Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82
Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids (2014) 0.82
Prescribing menopausal hormone therapy: an evidence-based approach. Int J Womens Health (2014) 0.81
Nanoparticle Estrogen in Rat Spinal Cord Injury Elicits Rapid Anti-Inflammatory Effects in Plasma, Cerebrospinal Fluid, and Tissue. J Neurotrauma (2015) 0.80
Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk. Clin Cancer Res (2014) 0.80
Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications. Onco Targets Ther (2014) 0.80
A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? Menopause (2014) 0.80
Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. Reprod Sci (2012) 0.79
Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells. Biochem Biophys Res Commun (2015) 0.79
Estrogen Protects against Obesity-Induced Mammary Gland Inflammation in Mice. Cancer Prev Res (Phila) (2015) 0.79
Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges. Oncotarget (2015) 0.79
Neuroprotective action of acute estrogens: animal models of brain ischemia and clinical implications. Steroids (2013) 0.78
GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure. Immunol Endocr Metab Agents Med Chem (2011) 0.78
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest (2016) 0.77
The transitioning from trials to extended follow-up studies. Clin Trials (2014) 0.77
Benefits of estrogen replacement for skeletal muscle mass and function in post-menopausal females: evidence from human and animal studies. Eurasian J Med (2011) 0.77
Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary study. J Womens Health (Larchmt) (2014) 0.77
Factors associated with successful discontinuation of hormone therapy. J Womens Health (Larchmt) (2014) 0.77
Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias? Eur J Epidemiol (2012) 0.77
Cancel the denosumab holiday. Osteoporos Int (2016) 0.76
Women's Health Initiative Hormone Therapy Trials: New insights on Cardiovascular Disease from Additional Years of Follow up. Curr Cardiovasc Risk Rep (2013) 0.76
Is timing everything? New insights into why the effect of estrogen therapy on memory might be age dependent. Endocrinology (2013) 0.76
Association of Mid-Life Changes in Body Size, Body Composition and Obesity Status with the Menopausal Transition. Healthcare (Basel) (2016) 0.76
The breast cancer epidemic: 10 facts. Linacre Q (2014) 0.76
A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age. Obstet Gynecol Int (2015) 0.76
Effect of prior oophorectomy on changes in bone mineral density and carotid artery intima-media thickness in postmenopausal women. Fertil Steril (2014) 0.76
Serum 2-methoxyestradiol, an estrogen metabolite, is positively associated with serum HDL-C in a population-based sample. Lipids (2011) 0.76
Ovariectomy is associated with metabolic impairments and enhanced mammary tumor growth in MKR mice. J Endocrinol (2015) 0.76
The tissue selective estrogen complex: a promising new menopausal therapy. Pharmaceuticals (Basel) (2012) 0.76
Breast cancer: Risk and mortality after oestrogen-alone therapy--is it safe? Nat Rev Clin Oncol (2012) 0.75
17β-Estradiol alters oxidative damage and oxidative stress response protein expression in the mouse mammary gland. Mol Cell Endocrinol (2016) 0.75
Vaginal Estrogen Therapy for Patients with Breast Cancer. Geburtshilfe Frauenheilkd (2013) 0.75
Estrogen and Cardiovascular Disease: Is Timing Everything? Am J Med Sci (2015) 0.75
Is Estrogen a Therapeutic Target for Glaucoma? Semin Ophthalmol (2016) 0.75
Prior hysterectomy and oophorectomy and incident venous thrombosis risk among postmenopausal women: a population-based, case-control study. Menopause (2016) 0.75
Interviews With Two Women's Health Experts On the Use of Estrogen Therapies. P T (2012) 0.75
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA (2000) 7.77
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Molecular and cellular basis of cardiovascular gender differences. Science (2005) 4.37
Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst (2011) 4.14
Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med (2003) 3.55
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA (2003) 3.04
Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol (2007) 2.85
Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) (2006) 2.77
Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med (1995) 2.58
Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology (1998) 2.18
Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol (2003) 2.02
Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol (2004) 1.68
Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol (2009) 1.52
Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA (2004) 1.50
Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res (2002) 1.49
Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med (2006) 1.40
Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol (2009) 1.35
Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol (2005) 1.23
Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med (2002) 1.22
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol (2010) 1.17
Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer (2009) 1.11
The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst (2011) 1.03
Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol (2010) 1.03
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Association of weight status with mortality in adults with incident diabetes. JAMA (2012) 7.49
A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med (2004) 6.77
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med (2014) 6.51
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16